Institutional Owners May Take Dramatic Actions as Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Recent 17% Drop Adds to One-year Losses
Institutional Owners May Take Dramatic Actions as Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Recent 17% Drop Adds to One-year Losses
Key Insights
主要見解
- Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their trading actions
- 52% of the business is held by the top 9 shareholders
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 強大的機構持股意味着Tenaya Therapeutics的股價對他們的交易行動非常敏感。
- 前9大股東持有業務的52%。
- 分析師預測以及所有者數據可以給我們提供有關業務前景的強烈想法。
If you want to know who really controls Tenaya Therapeutics, Inc. (NASDAQ:TNYA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 44% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正控制了Tenaya Therapeutics,Inc.(納斯達克股票代碼:TNYA),那麼你需要看看它的股權登記簿的構成。 佔有44%所有權的機構是擁有最大股份的群體。也就是說,如果股票上漲,該群體將最受益(或者如果出現經濟下滑將面臨最大風險)。
And so it follows that institutional investors was the group most impacted after the company's market cap fell to US$248m last week after a 17% drop in the share price. Needless to say, the recent loss which further adds to the one-year loss to shareholders of 49% might not go down well especially with this category of shareholders. Institutions or "liquidity providers" control large sums of money and therefore, these types of investors usually have a lot of influence over stock price movements. As a result, if the decline continues, institutional investors may be pressured to sell Tenaya Therapeutics which might hurt individual investors.
因此,當公司市值上週下跌17%的股價跌至2.48億美元后,機構投資者成爲受影響最大的群體。不用說,最近的損失進一步將股東一年的損失增加了49%,特別是對於這類股東而言,這可能不會很好。機構或“流動性提供者”控制着大量資金,因此這些類型的投資者通常對股票價格的波動有很大影響力。結果,如果下跌持續下去,機構投資者可能會受到壓力,被迫出售Tenaya Therapeutics的股權,這可能會傷害個人投資者。
Let's take a closer look to see what the different types of shareholders can tell us about Tenaya Therapeutics.
讓我們更仔細地看看不同類型的股東可以告訴我們有關Tenaya Therapeutics的信息。
![ownership-breakdown](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240620/0-36159d8a6f0281ab6598a8dfe77395d1-0-86ea8fff4c7197ce8e66b2b6eb4c61a8.png/big)
What Does The Institutional Ownership Tell Us About Tenaya Therapeutics?
機構投資的持股比例告訴我們關於Tenaya Therapeutics的信息
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
We can see that Tenaya Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Tenaya Therapeutics' earnings history below. Of course, the future is what really matters.
我們可以看到Tenaya Therapeutics確實有機構投資者;他們持有公司的很大一部分股票。這說明在專業投資者中存在一些可靠性。 但我們不能僅僅依靠這一事實,因爲機構有時會像其他人一樣犯下投資失敗。如果多個機構同時改變對一支股票的看法,那麼你可能會看到股價會迅速下跌。因此,值得看看下面的Tenaya Therapeutics盈利歷史。當然,未來才是真正重要的。
![earnings-and-revenue-growth](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240620/0-36159d8a6f0281ab6598a8dfe77395d1-1-59e326a9d6385fbd9560e91f5c891874.png/big)
Tenaya Therapeutics is not owned by hedge funds. The Column Group, LLC is currently the largest shareholder, with 12% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.6% and 7.3% of the stock.
Tenaya Therapeutics不是由對沖基金持有。 目前,具有12%流通股的是The Column Group,LLC是最大的股東。相比之下,第二大和第三大股東持有大約8.6%和7.3%的股份。
We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我們還觀察到,前9大股東持有超過股份註冊的一半,還有一些小股東平衡大股東的利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
儘管研究公司的機構持股可以增加您的研究價值,但研究分析師的建議也是一個好習慣,以更深入地了解股票的預期表現。有相當數量的分析師關注該股,因此了解他們對未來的總體觀點可能很有用。
Insider Ownership Of Tenaya Therapeutics
Tenaya Therapeutics的內部股東
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
內部人員的定義在不同國家之間可能略有不同,但董事會成員始終計數。公司管理層回答董事會,在此應代表股東利益。值得注意的是,有時高級管理人員也在董事會上。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。
Shareholders would probably be interested to learn that insiders own shares in Tenaya Therapeutics, Inc.. As individuals, the insiders collectively own US$2.8m worth of the US$248m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.
股東可能會想知道內部人員是否擁有Tenaya Therapeutics股份。作爲個人,內部人員共擁有價值280萬美元的這家市值爲2.48億美元的公司的股份。看到內部人員進行了一些投資是好的,但看看他們是否一直在購買股票可能更值得。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 27% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公衆,包括普通投資者,在公司擁有27%的股份,因此不能輕易被忽視。雖然這種所有權的規模可能不足以在他們的利益方面左右政策決策,但他們仍然可以對公司政策產生集體影響。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 28% stake in Tenaya Therapeutics. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
私募股權公司持有Tenaya Therapeutics的28%股權。這表明它們在重要政策決策方面具有影響力。一些投資者可能會因此感到鼓舞,因爲私募股權投資公司有時能夠鼓勵制定有助於市場看到公司價值的戰略。另外,這些持股人可能將其投資承銷後退出。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Tenaya Therapeutics better, we need to consider many other factors. For instance, we've identified 3 warning signs for Tenaya Therapeutics (1 is potentially serious) that you should be aware of.
考慮到公司股權結構是不錯的,但要了解Tenaya Therapeutics,還需要考慮許多其他因素。例如,我們爲Tenaya Therapeutics確定了3個警告信號(其中1個可能很重要)。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。